Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

96 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.
Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S. Hofbauer LC, et al. Among authors: lacey dl. Endocrinology. 1999 Oct;140(10):4382-9. doi: 10.1210/endo.140.10.7034. Endocrinology. 1999. PMID: 10499489
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.
Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Eghbali-Fatourechi G, et al. Among authors: lacey dl. J Clin Invest. 2003 Apr;111(8):1221-30. doi: 10.1172/JCI17215. J Clin Invest. 2003. PMID: 12697741 Free PMC article.
Osteoclast differentiation and activation.
Boyle WJ, Simonet WS, Lacey DL. Boyle WJ, et al. Among authors: lacey dl. Nature. 2003 May 15;423(6937):337-42. doi: 10.1038/nature01658. Nature. 2003. PMID: 12748652 Review.
Interleukin 4, interferon-gamma, and prostaglandin E impact the osteoclastic cell-forming potential of murine bone marrow macrophages.
Lacey DL, Erdmann JM, Teitelbaum SL, Tan HL, Ohara J, Shioi A. Lacey DL, et al. Endocrinology. 1995 Jun;136(6):2367-76. doi: 10.1210/endo.136.6.7750457. Endocrinology. 1995. PMID: 7750457
The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.
Padagas J, Colloton M, Shalhoub V, Kostenuik P, Morony S, Munyakazi L, Guo M, Gianneschi D, Shatzen E, Geng Z, Tan HL, Dunstan C, Lacey D, Martin D. Padagas J, et al. Among authors: lacey d. Calcif Tissue Int. 2006 Jan;78(1):35-44. doi: 10.1007/s00223-005-0161-1. Epub 2005 Dec 5. Calcif Tissue Int. 2006. PMID: 16362459
Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats.
Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik PJ. Capparelli C, et al. Among authors: lacey d. J Bone Miner Res. 2003 May;18(5):852-8. doi: 10.1359/jbmr.2003.18.5.852. J Bone Miner Res. 2003. PMID: 12733724
Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice.
Clohisy DR, Ramnaraine ML, Scully S, Qi M, Van G, Tan HL, Lacey DL. Clohisy DR, et al. Among authors: lacey dl. J Orthop Res. 2000 Nov;18(6):967-76. doi: 10.1002/jor.1100180617. J Orthop Res. 2000. PMID: 11192258
The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development.
Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM. Fata JE, et al. Among authors: lacey dl. Cell. 2000 Sep 29;103(1):41-50. doi: 10.1016/s0092-8674(00)00103-3. Cell. 2000. PMID: 11051546
Osteoprotegerin mitigates tail suspension-induced osteopenia.
Bateman TA, Dunstan CR, Ferguson VL, Lacey DL, Ayers RA, Simske SJ. Bateman TA, et al. Among authors: lacey dl. Bone. 2000 May;26(5):443-9. doi: 10.1016/S8756-3282(00)00256-8. Bone. 2000. PMID: 10773583
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.
Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. Hofbauer LC, et al. Among authors: lacey dl. J Bone Miner Res. 2000 Jan;15(1):2-12. doi: 10.1359/jbmr.2000.15.1.2. J Bone Miner Res. 2000. PMID: 10646108 Review.
96 results
Jump to page